Turning the Tide on Cancer Drug Costs

The Presentation inside:

Slide 0

Turning the tide on cancer drug costs A rising tide of new cancer drugs helps patients. >700% 117 Since 1990, new cancer drugs have been approved in the US. 2 50 Another could reach the market by 2020.1 3 This wave of innovation could drown payers. To hold back the tide of oncology drug costs, payers … ... limit patient access Since 2006, NICE has issued negative recommendations for of the cancer drugs reviewed.3 41% 4 The increase in the median monthly cost of cancer drugs in the US since 1990 2 ... experiment with new models $ US payers test indication-specific pricing, taking advantage of four new drug value tools. Innovative risk-sharing agreements are another way to turn the tide. The number of risk-sharing contracts created in the UK and Italy since 2006 90 65% of the contracts are for cancer drugs.4 These contracts are complex to build, but can provide a strong foundation for patient access. Sources: 1 U.S. Food & Drug Administration, Memorial Sloan Kettering Cancer Center, Decision Resources. 2 Peter Bach, Memorial Sloan Kettering Cancer Center, Center for Health Policy and Outcomes, "Price and Value of Cancer Drug," 2015. 3 EY, National Institute for Health and Care Excellence (NICE). 4 Van de Vooren, et al., “Market-access agreements for anti-cancer drugs,” J R Soc Med (108): 166–170, 2015. © 2015 EYGM Limited. All Rights Reserved. EYG no. FN0236. ED None 1

Slide 1